McKesson releases 3Q FY05 results

McKesson Corp. reported that revenues for the third quarter FY05 ending December 31 were $20.8 billion, an increase of 14 percent from $18.2 billion in the year-ago quarter.
   
For the quarter, McKesson had a net loss of $655 million including the previously announced after tax-charge of $810 million for settling the company's consolidated securities class action and reserves for remaining related cases. Not including the securities litigation charge, McKesson had net income of $145 million compared with $120 million in the year-ago quarter.
   
For the nine-month period, sales increased 16 percent to $59.9 million, compared with $51.6 million in the first nine months of FY04. Net income, excluding securities litigation charge decreased 9 percent to $394.3 million, compared with $432.3 million in the year-ago period.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup